United Therapeutics Corporation (UTHR)

業務介紹

聯合治療公司是一家生物技術公司,致力於開發和商業化產品,以解決美國和國際上患有慢性和危及生命的疾病患者的未滿足的醫療需求。其商業療法包括:

1. Remodulin,用於治療肺動脈高血壓(PAH)患者,以減輕運動相關的症狀。
2. Tyvaso,一種吸入型前列環素類似物曲美布汀的製劑,可提高PAH患者和間質性肺病相關肺高血壓(PH-ILD)患者的運動能力。
3. Orenitram,一種曲美布汀的片劑劑型,可提高PAH患者的運動能力。
4. Unituxin,一種單克隆抗體,用於治療高危神經母細胞瘤。
5. Adcirca,一種口服PDE-5抑制劑,可提高PAH患者的運動能力。

該公司還在開發以下產品:Tyvaso DPI(Tyvaso的乾粉吸入劑型)、Remunity Pump(一種小型、輕便、耐用的泵和單獨的控制器)、RemoPro和Ralinepag(用於治療PAH)、Aurora-GT(一種基因療法產品,用於重建肺部血管)以及Tyvaso PERFECT和TETON研究(研究Tyvaso在WHO第3組慢性阻塞性肺病相關肺高血壓(PH-COPD)患者中的作用)。

該公司還與DEKA Research & Development Corp.、MannKind Corporation和Arena Pharmaceuticals, Inc.簽有許可和合作協議,共同開發和許可相關產品。該公司成立於1996年,總部位於馬里蘭州銀泉。



United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

公司網址

https://www.unither.com